- Trials with a EudraCT protocol (95)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
95 result(s) found for: Mixed episode.
Displaying page 1 of 5.
EudraCT Number: 2004-000915-25 | Sponsor Protocol Number: D1447C00144 | Start Date*: 2005-04-22 | |||||||||||
Sponsor Name:AstraZeneca R&D Sodertalje | |||||||||||||
Full Title: Multicenter, Randomized, Parallel-group, Double-blind, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate and Lithium as Monotherapy for up to 104 weeks Maintenanc... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001935-30 | Sponsor Protocol Number: ELND005-BPD201 | Start Date*: 2012-11-27 |
Sponsor Name:Elan Pharma International Ltd | ||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Safety and Efficacy Study of Oral ELND005 as an Adjunctive Maintenance Treatment in Patients with Bipolar I Disorder | ||
Medical condition: Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) ES (Completed) LT (Prematurely Ended) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000803-25 | Sponsor Protocol Number: RGH-MD-25 | Start Date*: 2019-10-02 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER CLINICAL TRIAL EVALUATING THE EFFICACY, SAFETY, AND TOLERABILITY OF CARIPRAZINE IN A DOSE-REDUCTION PARADIGM IN THE PREVENTION... | ||||||||||||||||||
Medical condition: Bipolar I disorder | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) RO (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001308-11 | Sponsor Protocol Number: F1D-XM-HGLW | Start Date*: 2004-08-19 | |||||||||||
Sponsor Name:Lilly.S.A. | |||||||||||||
Full Title: Optimal Treatment Duration with Olanzapine following Remission of Manic or Mixed Episode. An Open-Label, Randomized Trial Comparing Two Treatment Strategies | |||||||||||||
Medical condition: to compare the efficacy in the prevention of relapse to manic, depressive, or mixed episodes in two groups of bipolar I patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-005812-25 | Sponsor Protocol Number: R076477BIM3002 | Start Date*: 2006-03-07 |
Sponsor Name:Janssen-Cilag International N.V. | ||
Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Flexibly-Dosed Extended-Release Paliperidone Compared with Flexi... | ||
Medical condition: Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) GR (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-001482-17 | Sponsor Protocol Number: F1D-MC-HGKQ(b) | Start Date*: 2004-10-15 |
Sponsor Name:Eli Lilly and Company | ||
Full Title: Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar I disorder. | ||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: LT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-001490-15 | Sponsor Protocol Number: RIS-BMN-3001 | Start Date*: 2007-04-23 | |||||||||||
Sponsor Name:Janssen-Cilag International N.V | |||||||||||||
Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the... | |||||||||||||
Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000606-20 | Sponsor Protocol Number: A1281132 | Start Date*: 2015-04-03 |
Sponsor Name:Pfizer, Inc. | ||
Full Title: Four Week, Double-Blind, Placebo Controlled Phase III Trial Evaluating The Efficacy, Safety And Pharmacokinetics Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Dis... | ||
Medical condition: Bipolar Disorder | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2021-002126-24 | Sponsor Protocol Number: SEP380-301 | Start Date*: 2022-02-02 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A Multi-region, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating SEP-4199 Controlled Release (CR) for the Treatment of Major Depressive Episode Associated ... | |||||||||||||
Medical condition: Major Depressive Episode Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) SK (Prematurely Ended) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018409-13 | Sponsor Protocol Number: P05691 | Start Date*: 2012-08-23 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering | |||||||||||||
Full Title: A Phase 3b, Multicenter, Double-Blind, Fixed-Dose, Parallel-Group, Three Week Placebo Controlled Trial Evaluating the Safety and Efficacy of Asenapine in Subjects With Bipolar 1 Disorder Experie... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-000986-10 | Sponsor Protocol Number: D1050296 | Start Date*: 2011-12-14 | |||||||||||
Sponsor Name:Sunovion Pharmaceuticals Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, FLEXIBLE-DOSE, PARALLEL-GROUP STUDY OF LURASIDONE ADJUNCTIVE TO LITHIUM OR DIVALPROEX FOR THE PREVENTION OF RECURRENCE IN SUBJECTS WITH BIPOLAR I DISO... | |||||||||||||
Medical condition: Bipolar disorder I depression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) CZ (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-003781-14 | Sponsor Protocol Number: RISBIM3003 | Start Date*: 2004-12-02 |
Sponsor Name:Johnson & Johnson Pharmaceutical Research and Development | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of Risperidone Long-Acting Intramuscular Injectable in the Prevention of Mood Episodes in Bipolar I Disorder,... | ||
Medical condition: BIPOLAR MANIA | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-018671-20 | Sponsor Protocol Number: P06384 | Start Date*: 2012-08-24 | |||||||||||
Sponsor Name:Forest Research Institute Inc., a wholly owned subsidiary of Forest Laboratories, LLC | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Trial of Asenapine in the Prevention of Recurrence of a Mood Episode After Stabilization of an Acute Manic/Mixed Episode in Subjects With Bipolar 1 Disorder (Phas... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-022647-38 | Sponsor Protocol Number: P06107 | Start Date*: 2011-11-16 | |||||||||||
Sponsor Name:Schering-Plough Research Institute, a Division of Schering Corporation | |||||||||||||
Full Title: Efficacy and Safety of 3-Week Fixed-Dose Asenapine Treatment in Pediatric Acute Manic or Mixed Episodes Associated with Bipolar I Disorder (Protocol No. P06107) | |||||||||||||
Medical condition: Acute Manic or Mixed Episodes Associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002870-30 | Sponsor Protocol Number: 31-08-250 | Start Date*: 2013-01-13 | |||||||||||
Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc. | |||||||||||||
Full Title: A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Ma... | |||||||||||||
Medical condition: Bipolar I disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000202-49 | Sponsor Protocol Number: CN138-134 | Start Date*: 2005-02-22 |
Sponsor Name:Bristol-Myers Squibb International Corporation | ||
Full Title: Efficacy of Aripiprazole in Combination with Valproate or Lithium in the Treatment of Mania in Patients with Bipolar I Disorder Partially Nonresponsive to Valproate or Lithium Monotherapy Revised... | ||
Medical condition: Bipolar disorder | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: EE (Completed) HU (Completed) ES (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-000846-38 | Sponsor Protocol Number: R076477-BIM-3004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Janssen-Cilag International N.V. | |||||||||||||
Full Title: A Randomized, Double-Blind, Active- and Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Extended-Release Paliperidone as Maintenance Treatment After an ... | |||||||||||||
Medical condition: Bipolar I disorder, most recent maniac or mixed episode | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-002131-27 | Sponsor Protocol Number: SCO/BIA-2093-203 | Start Date*: 2005-09-27 |
Sponsor Name:BIAL - Portela & Ca, S.A. | ||
Full Title: Efficacy and safety of eslicarbazepine acetate (BIA 2-093) in acute manic episodes associated with bipolar I disorder in a double-blind, randomised, dose-titration, placebo-controlled, multicenter ... | ||
Medical condition: Patients with acute manic episode fulfilling DSM-IV criteria for Bipolar I Disorder (i.e., 296.0, 296.4 or 296.6) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) SK (Completed) CZ (Completed) DE (Completed) PT (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-003927-11 | Sponsor Protocol Number: A7501008 | Start Date*: 2005-08-04 | |||||||||||
Sponsor Name:NV Organon | |||||||||||||
Full Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or ValproicAcid/Divalproex Sodium for the Treatment of... | |||||||||||||
Medical condition: Bipolar 1 Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-004167-27 | Sponsor Protocol Number: A1281137 Amendment 1 | Start Date*: 2006-01-25 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: A Phase 3, randomized, 6-month, double blind trial in subjects with Bipolar I Disorder to evaluate the continued safety and maintenance of effect of Ziprasidone plus a mood stabilizer (vs placebo p... | |||||||||||||
Medical condition: Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) IT (Completed) SE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
